Member Info for Lionel1

@left to hang , You are another STU .

Why ??? Why ?? Why ??

@stock ,

https://www.thebusinessdesk.com/northwest/news/2125152-second-nhs-trust-adopts-genedrives-hearing-loss-testing-kit-for-routine-use

Commercial distribution agreements for the AIHL test are in place covering Spain, France, Austria, Greece, Saudi Arabia, Kuwait, Turkey and the Netherlands.

I think it’s being used in Liverpool women’s hospital since the pilot from 2020 , PALOH study .

Blind leading another blind …:-)

Get well soon Stu , what’s your pHD subject anyway ? Spending /wasting time on the share you are not invested ??

@Stu , I think you should go and tell Manchester and Liverpool NHS trusts that they are wasting time on bedside stroke test.. :-) ..

https://www.northerncarealliance.nhs.uk/news/nca-news/manchester-leads-implementation-lifesaving-genetic-bedside-stroke-test

Professor Newman, who is also Rare Conditions Co-Theme Lead at the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC), added: “This could reduce time spent in hospital, prevent further strokes, save lives, and avoid future hospital admissions.

“If adopted into routine practice, this rapid test, which has been recommended for use in the NHS by the National Institute for Health and Care Excellence (NICE), represents a major transformation in the way we manage stroke in this country.

“Our early model-based cost-effectiveness analysis published last year shows that using a rapid genetic test could lead to significant cost savings for the NHS. Using a rapid genetic test was £512 less expensive compared with no testing per patient, due to the prevention of secondary strokes and reduced hospital admissions. When you factor in the potential improvements in a patients’ quality of life, the model estimates that the potential saving to the NHS is over £160 million each year.”

Using a simple cheek swab, the non-invasive test can be performed at the bedside. From the swab, the genedrive system interprets the genetic information on the patient and informs the clinician with options on the course of treatment.

Previously, genetic testing for CYP2C19 could only be carried out using specialist laboratories, a process which can take several days.

The innovative test was used at Manchester Royal Infirmary and the Manchester Centre for Genomic Medicine, Saint Mary’s Hospital, both part of MFT, over six months, to evaluate performance in the clinical setting.

You are missing the whole point…..You are entitled to have an opinion but you can’t change the facts ..

Exploring rapid testing

NICE recommends laboratory testing where possible, but is also supportive of a POCT that Dr McDermott and his team have been involved in developing that could help the NHS implement this new guidance more quickly.

“[Our group has] been involved in the development and validation of different rapid point-of-care tests,” Dr McDermott explains. “With a company called Genedrive, here in Manchester, we’ve developed a test where you take a cheek swab and put it into a machine and it will produce a result to help guide anti-platelet therapy within an hour. It’s a really exciting development that we’ve just finished validating and the results are extremely impressive.”

Such rapid testing has many advantages, including being able to offer alternative treatments to patients much sooner and easing pressures on the wider healthcare system.

Another one .

https://academic.oup.com/ehjcvp/advance-article/doi/10.1093/ehjcvp/pvae040/7739585?searchresult=1

I think there is a circular went out to all NHS trusts about the clopidogrel prescribing and things to consider before prescribing. We will hear more soon ..

Excellent article in support of Rapid POC from Genedrive ..Very Happy that NHS support by the technology .

https://www.genomicseducation.hee.nhs.uk/blog/nice-approves-genomic-test-to-prevent-secondary-strokes/

Lol Gloria , Thank you .. We all will be rewarded one day but no one knows when , hope that day comes before I retire ..

Https://www.rcn.org.uk/news-and-events/Blogs/nice-recommends-cyp2c19-genotype-testing-to-personalise-clopidogrel-use-for-stroke-and-tia

@Stfu,

With all the “apparent “ disadvantages you repeatedly pronounce, why would you waste your time here ?

STFU

Https://pharmaceutical-journal.com/article/news/more-than-2000-patients-tested-in-uks-first-routine-genotyping-project-for-clopidogrel-prescribing

I see few shorters trying their luck and some resident rodents joined the chorus ..

my ai bot says …

the predicted 95.39% rise in genedrive's stock price over the next three months is influenced by several factors. the company has seen increased demand for its genedrive mt-rnr1 id kit, which has been pivotal in preventing antibiotic-induced hearing loss in newborns[4]. additionally, the company has secured orders from multiple uk hospitals and received positive regulatory news, such as the "breakthrough device designation" from the us fda[3][4]. these developments, along with strategic partnerships and market expansion efforts, contribute to the optimistic forecast[4].

sources

[1] genedrive plc stock price forecast. should you buy gdr.l? https://stockinvest.us/stock/gdr.l

[2] in brief: genedrive completes placing portion of gbp6 million raise https://www.morningstar.co.uk/uk/news/an_1715339437821719900/in-brief-genedrive-completes-placing-portion-of-gbp6-million-raise.aspx

[3] genedrive shares (lon: gdr) - forecasts & price targets https://www.asktraders.com/shares/lon/gdr-genedrive-forecast/

[4] genedrive plc: a 2024 analysis and future outlook https://uk.investing.com/analysis/genedrive-plc-a-2024-analysis-and-future-outlook-200611794

[5] genedrive stock forecast: down to 0.00000147 gbx? - gdr stock price prediction, long-term & short-term share revenue prognosis with smart technical analysis https://walletinvestor.com/lse-stock-forecast/gdr-stock-prediction

[6] gdr — genedrive share price https://www.stockopedia.com/share-prices/genedrive-lon:gdr/

[7] in brief: genedrive aims to raise at least gbp6 million in share offer https://www.morningstar.co.uk/uk/news/an_1715320808530696000/in-brief-genedrive-aims-to-raise-at-least-gbp6-million-in-share-offer.aspx

[8] genedrive plc equity research & stock reports https://*********************/companies/uk/health/genedrive-plc/gdr/lon

Lol Tkevin , what have u been smoking last night .. :-)

This board is completely taken over by id**ts , emeralds and systemzeros… emerald for godsake stop it dude :-)

Great days ahead…

https://www.tandfonline.com/doi/full/10.1080/14622416.2024.2366691?src=

Summary :

The state of Hawaii was awarded $916 million this year in a lawsuit that asserted the makers of Plavix (clopidogrel) didn't do enough to get the word out that *2/*3 variants of CYP2C19 rendered the drug ineffective.

The variant is thought to be more highly expressed among people with Asian ancestry, and for a fourth-generation fisherman named Rudy, this bias led to his untimely death. As described in an editorial in Personalized Medicine, despite diligently taking clopidogrel every day for three months after undergoing angioplasty and stent surgery, Rudy died of a heart attack on the way to hospital. His autopsy revealed complete arterial blockage at the stent site and post-mortem genetic testing uncovered his *2/*3 variant status.

Clopidogrel, sold under the brand name Plavix among others, is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk.